Skip to main content
logo
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG:3378)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
27.40
-1.44 (-4.99%)
Sep 11, 2026, 4:08 PM HKT

HKG:3378 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Other Revenue
0.070.092.22.54
Revenue
0.070.092.22.54
Revenue Growth
--95.82%-13.39%-
Gross Profit
0.070.092.22.54
Selling, General & Admin
59.9158.0646.1917.22
Research & Development
84.1589.3674.7246.66
Other Operating Expenses
-2.52-2.19--
Operating Expenses
141.54145.24120.9163.88
Operating Income
-141.47-145.14-118.71-61.34
Interest Expense
-7.12-11.62-9.38-2.28
Interest & Investment Income
6.10.362.924.13
Currency Exchange Gain (Loss)
-0.01-0.94-0.65
Other Non Operating Income (Expenses)
-19.72-2.61-0.21-0.08
EBT Excluding Unusual Items
-162.23-159.02-124.44-60.22
Gain (Loss) on Sale of Investments
30.2513.981.62-33.2
Pretax Income
-131.98-145.04-122.82-93.42
Income Tax Expense
-0.9-13.54-5.9-8.26
Earnings From Continuing Operations
-131.08-131.49-116.92-85.16
Minority Interest in Earnings
-0.370.491.099.1
Net Income
-131.45-131.01-115.83-76.06
Net Income to Common
-131.45-131.01-115.83-76.06
Net Income Growth
----
Shares Outstanding (Basic)
1271181187
Shares Outstanding (Diluted)
1271181187
Shares Change
8.28%0.34%1516.00%-
EPS (Basic)
-1.03-1.11-0.98-10.42
EPS (Diluted)
-1.03-1.11-0.98-10.42
EPS Growth
----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23
Free Cash Flow
--104.22-111.1-56.23
Free Cash Flow Per Share
--0.88-0.94-7.71
Gross Margin
100.00%100.00%100.00%100.00%
Operating Margin
-193791.78%-157764.13%-5398.55%-2416.07%
Profit Margin
-180068.49%-142398.91%-5267.39%-2995.51%
Free Cash Flow Margin
--113280.44%-5052.48%-2214.49%
EBITDA
-138.13-142.25-116.7-60.83
D&A For EBITDA
3.342.92.020.52
EBIT
-141.47-145.14-118.71-61.34